Pegylated interferon-alpha-2a

Pegylated interferon-alpha-2a

Clinical data
Pregnancy category	?
Routes of administration	?
ATC code	L03AB11 (WHO)
Legal status
Legal status	?
Pharmacokinetic data
Bioavailability	?
Metabolism	?
Elimination half-life	?
Excretion	?
Identifiers
CAS Number	215647-85-1
DrugBank	BTD00043
E number	{{#property:P628}}
ECHA InfoCard	{{#property:P2566}}
Chemical and physical data
Formula	C860H1353N227O255S9
Molar mass	19241 g/mol

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Please Take Over This Page and Apply to be Editor-In-Chief for this topic: There can be one or more than one Editor-In-Chief. You may also apply to be an Associate Editor-In-Chief of one of the subtopics below. Please mail us [2] to indicate your interest in serving either as an Editor-In-Chief of the entire topic or as an Associate Editor-In-Chief for a subtopic. Please be sure to attach your CV and or biographical sketch.

Overview

Pegylated interferon alfa-2a (40kD) (commercial name PEGASYS) is an antiviral drug discovered at the pharmaceutical company F.Hoffmann-La Roche; it has a dual mode of action - both antiviral and on the immune system.

This drug is approved around the world for the treatment of chronic hepatitis C (including patients with HIV co-infection, cirrhosis, 'normal' levels of ALT) and has recently been approved (in the EU, U.S., China and many other countries) for the treatment of chronic hepatitis B.

Related Chapters

• Interferon
• PEGylation

External links

• PMPRB at pmprb-cepmb.gc.ca
• Pegasys at the US National Library of Medicine Medical Subject Headings (MeSH)